Lycopene and Soy Isoflavones in the Treatment of Prostate Cancer

Abstract Dietary intake of lycopene and soy has been associated with a lower risk of prostate cancer. In vitro studies with lycopene and genistein, a soy isoflavone, have shown induction of apoptosis and inhibition of cell growth in androgen-sensitive (LNCaP) and androgen–independent (PC3 and VeCaP) prostate cancer cell lines. In a previous Phase II clinical trial in prostate cancer patients, we observed prostate-specific antigen (PSA) stabilization with soy isoflavone intake. In this Phase II clinical trial, we investigated the efficacy of lycopene alone or in combination with soy isoflavones on serum PSA levels in men with prostate cancer. To be eligible for the study, men with prostate cancer had to have rising serum PSA following local therapy or while on hormone therapy. Study population included 71 eligible patients who had 3 successive rising PSA levels or a minimum PSA of 10 ng/ml at 2 successive evaluations prior to starting therapy. Subjects were randomly assigned to receive a tomato extract capsule containing 15 mg of lycopene alone (n = 38) or together with a capsule containing 40 mg of a soy isoflavone mixture (n = 33) twice daily orally for a maximum of 6 mo. One patient on the lycopene arm did not receive therapy due to his inability to ingest the study pill. There was no decline in serum PSA in either group qualifying for a partial or complete response. However, 35 of 37 (95%) evaluable patients in the lycopene group and 22 of 33 (67%) evaluable patients in the lycopene plus soy isoflavone group achieved stable disease described as stabilization in serum PSA level. The data suggest that lycopene and soy isoflavones have activity in prostate cancer patients with PSA relapse disease and may delay progression of both hormone-refractory and hormone-sensitive prostate cancer. However, there may not be an additive effect between the 2 compounds when taken together. Future studies are warranted to further investigate the efficacy of lycopene and soy isoflavones in prostate cancer as well as the mechanism of potential negative interaction between them.

[1]  M. Murakoshi,et al.  Cancer prevention by carotenoids , 1999, Archives of biochemistry and biophysics.

[2]  Ferenc Zsila,et al.  Molecular modeling of the non-covalent binding of the dietary tomato carotenoids lycopene and lycophyll, and selected oxidative metabolites with 5-lipoxygenase. , 2006, Bioorganic & medicinal chemistry.

[3]  Peter Clark,et al.  Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. , 2006, Urology.

[4]  H. Moriwaki,et al.  Suppression by carotenoids of microtenoids of microcystin-induced morphological changes in mouse hepatocytes , 1995, Lipids.

[5]  R. Aluko,et al.  The anti-carcinogenic and anti-atherogenic effects of lycopene: a review , 2005 .

[6]  O. Bratt.  A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer , 2004, BJU international.

[7]  K. Wertz,et al.  Lycopene and Vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  L. Beckett,et al.  Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. , 2004, Urology.

[9]  N. Gupta,et al.  A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer , 2003, BJU international.

[10]  B. Chew,et al.  Carotenoid action on the immune response. , 2004, The Journal of nutrition.

[11]  M. Banerjee,et al.  Soy Isoflavones in the Treatment of Prostate Cancer , 2003, Nutrition and cancer.

[12]  E. Giovannucci.  A Review of Epidemiologic Studies of Tomatoes, Lycopene, and Prostate Cancer , 2002, Experimental biology and medicine.

[13]  E. Rimm,et al.  A prospective study of tomato products, lycopene, and prostate cancer risk. , 2002, Journal of the National Cancer Institute.

[14]  R. V. van Breemen,et al.  Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. , 2001, Journal of the National Cancer Institute.

[15]  M. Banerjee,et al.  Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  M. Pollak,et al.  Insulin-like growth factors and prostate cancer. , 2001, Epidemiologic reviews.

[17]  N. Fleshner,et al.  Serum and tissue lycopene and biomarkers of oxidation in prostate cancer patients: a case control study , 2000, Prostate Cancer and Prostatic Diseases.

[18]  M. Gleave,et al.  Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. , 2000, Cancer research.

[19]  Elizabeth J Johnson.  The Role of Lycopene in Health and Disease , 2000 .

[20]  M. Karas,et al.  Lycopene Interferes With Cell Cycle Progression and Insulin-Like Growth Factor I Signaling in Mammary Cancer Cells , 2000, Nutrition and cancer.

[21]  J. Bertram.  Carotenoids and gene regulation. , 2009, Nutrition reviews.

[22]  W. Keung,et al.  Bovine adrenal 3β-hydroxysteroid dehydrogenase (E.C. 1.1.1.145)/5-ene-4-ene isomerase (E.C. 5.3.3.1): characterization and its inhibition by isoflavones , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  P. Cohen,et al.  Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. , 1999, The Journal of endocrinology.

[24]  E. Giovannucci.  Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Cancer , 1999, Hormone Research in Paediatrics.

[25]  B. Freidlin,et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. Blackburn,et al.  Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. , 1999, The Journal of nutrition.

[27]  D. Gius,et al.  Intracellular oxidation/reduction status in the regulation of transcription factors NF-kappaB and AP-1. , 1999, Toxicology letters.

[28]  P. Riso,et al.  Does tomato consumption effectively increase the resistance of lymphocyte DNA to oxidative damage? , 1999, The American journal of clinical nutrition.

[29]  N. O'Brien,et al.  Effect of dietary supplementation with carotenoids on xenobiotic metabolizing enzymes in the liver, lung, kidney and small intestine of the rat , 1999, British Journal of Nutrition.

[30]  M. Karas,et al.  Lycopene and 1,25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. , 1999, Nutrition and cancer.

[31]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.

[32]  C. Mantzoros,et al.  Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. , 1998, Journal of the National Cancer Institute.

[33]  Z. Shao,et al.  Genistein inhibits proliferation similarly in estrogen receptor‐positive and negative human breast carcinoma cell lines characterized by P21WAF1/CIP1 induction, G2/M arrest, and apoptosis , 1998, Journal of cellular biochemistry.

[34]  H. Huynh,et al.  Castration-Induced Apoptosis in the Rat Ventral Prostate Is Associated with Increased Expression of Genes Encoding Insulin-Like Growth Factor Binding Proteins 2, 3, 4 and 5. , 1998, Endocrinology.

[35]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[36]  F. Sarkar,et al.  Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. , 1998, Nutrition and cancer.

[37]  H. Huynh,et al.  Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5. , 1998, Endocrinology.

[38]  Y. Ishimi,et al.  Vitamin A and carotenoids stimulate differentiation of mouse osteoblastic cells. , 1997, Journal of nutritional science and vitaminology.

[39]  P. Cohen,et al.  Insulin-like Growth Factor (IGF)-binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-independent Mechanism* , 1997, The Journal of Biological Chemistry.

[40]  F. Khachik,et al.  Cancer prevention by natural carotenoids. , 1997, Journal of cellular biochemistry. Supplement.

[41]  H. Wei,et al.  Effect of structurally related flavones/isoflavones on hydrogen peroxide production and oxidative DNA damage in phorbol ester-stimulated HL-60 cells. , 1997, Nutrition and cancer.

[42]  C. Mantzoros,et al.  Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. , 1997, British Journal of Cancer.

[43]  D. C. Knight,et al.  A REVIEW OF THE CLINICAL EFFECTS OF PHYTOESTROGENS , 1996, Obstetrics and gynecology.

[44]  R. Rahn,et al.  Inhibition of UV light- and Fenton reaction-induced oxidative DNA damage by the soybean isoflavone genistein. , 1996, Carcinogenesis.

[45]  J. Bertram,et al.  Dietary carotenoids inhibit neoplastic transformation and modulate gene expression in mouse and human cells. , 1995, The American journal of clinical nutrition.

[46]  H. Adlercreutz.  Phytoestrogens: epidemiology and a possible role in cancer protection. , 1995, Environmental health perspectives.

[47]  P. Ao,et al.  Connexin43 reverses the phenotype of transformed cells and alters their expression of cyclin/cyclin-dependent kinases. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[48]  E. Giovannucci.  Epidemiologic Characteristics of Prostate Cancer , 1995 .

[49]  M. Danilenko,et al.  Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene. , 1995, Nutrition and cancer.

[50]  H. Moriwaki,et al.  Suppression by carotenoids of microcystin-induced morphological changes in mouse hepatocytes. , 1995, Lipids.

[51]  H. Adlercreutz,et al.  Genistein, a dietary-derived inhibitor of in vitro angiogenesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[52]  A. Hotz-Wagenblatt,et al.  Gap junctional communication and neoplastic transformation. , 1993, Critical reviews in oncogenesis.

[53]  J. Bertram,et al.  Carotenoids up-regulate connexin43 gene expression independent of their provitamin A or antioxidant properties. , 1992, Cancer research.

[54]  J. Bertram,et al.  Carotenoids enhance gap junctional communication and inhibit lipid peroxidation in C3H/10T1/2 cells: relationship to their cancer chemopreventive action. , 1991, Carcinogenesis.

[55]  W. Schalch,et al.  The singlet oxygen and carotenoid interaction. , 1991, Journal of photochemistry and photobiology. B, Biology.

[56]  B. Henderson,et al.  Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. , 1991, British Journal of Cancer.

[57]  J. Bertram,et al.  Diverse carotenoids protect against chemically induced neoplastic transformation. , 1991, Carcinogenesis.

[58]  H. Yamasaki.  Gap junctional communication and carcinogenesis , 1990 .

[59]  H. Yamasaki,et al.  Gap junctional intercellular communication and carcinogenesis. , 1990, Carcinogenesis.

[60]  T. Campbell,et al.  Effects of carotenoids on aflatoxin B1-induced mutagenesis in S. typhimurium TA 100 and TA 98. , 1990, Nutrition and cancer.

[61]  P. Di Mascio,et al.  Lycopene as the most efficient biological carotenoid singlet oxygen quencher. , 1989, Archives of biochemistry and biophysics.

[62]  W. Loewenstein,et al.  Enhancement of gap junctional communication by retinoids correlates with their ability to inhibit neoplastic transformation. , 1989, Carcinogenesis.

[63]  W. L. Beeson,et al.  Cohort study of diet, lifestyle, and prostate cancer in adventist men , 1989, Cancer.

[64]  W. Loewenstein,et al.  The actions of retinoids on cellular growth correlate with their actions on gap junctional communication , 1989, The Journal of cell biology.

[65]  T. Yoshinari,et al.  Effect of genistein on topoisomerase activity and on the growth of [Val 12]Ha-ras-transformed NIH 3T3 cells. , 1988, Biochemical and biophysical research communications.

[66]  D. Paul,et al.  Connexin43: a protein from rat heart homologous to a gap junction protein from liver , 1987, The Journal of cell biology.

[67]  M. Shibuya,et al.  Genistein, a specific inhibitor of tyrosine-specific protein kinases. , 1987, The Journal of biological chemistry.

[68]  E. Wynder,et al.  International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption , 1986 .

[69]  W. Loewenstein,et al.  Growth inhibition of transformed cells correlates with their junctional communication with normal cells , 1986, Cell.

[70]  E. Wynder,et al.  International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. , 1986, Cancer.

[71]  W. Loewenstein,et al.  Junctional intercellular communication and the control of growth. , 1979, Biochimica et biophysica acta.